NervGen Pharma Corp. (NGENF: OTCQB) | NervGen Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference. Key details include:
- CEO Mike Kelly will participate in a fireside chat on February 11, 2025, at 8:40 a.m. EST.
- The conference will be held virtually from February 11-12, 2025.
- NervGen’s management team will be available for one-on-one virtual meetings with investors during the event.
- A webcast of the presentation will be made available for later viewing.
NervGen is a clinical-stage biotech company focused on developing neurorestorative therapeutics. Their lead molecule, NVG-291, is currently in a Phase 1b/2a clinical trial for spinal cord injury. The company has also initiated preclinical evaluation of a new candidate, NVG-300, for ischemic stroke, ALS, and spinal cord injury models.NVG-291, NervGen’s flagship product, has received Fast Track designation from the FDA for spinal cord injury treatment. It is designed to promote nervous system repair and has shown promising results in preclinical studies, including neuroplasticity promotion, remyelination, and functional improvement in various injury models.
Source link
#NervGen #Pharma #Corp #NGENF #OTCQB #NervGen #Pharma #Present #Oppenheimer #35th #Annual #Healthcare #Life #Sciences #Conference
PressAlchemy helps businesses of all size from startups to established companies to turn their news into headlines. Whether you’re announcing a corporate update, sharing a major project milestone, or launching a new product, press release distribution ensures your story reaches the right audience on top platforms. If you own a business or have a story to share, now’s the time to get noticed.
Expand your reach to 900+ Media Networks, 13.3k Journalists, and a global audience of over a billion users! Get your Press Release or Article featured for your business or story – CLICK HERE.
